Did you know that the extract from a fruit can keep the rogue cells of twelve different types of cancer in check?
According to media, the graviola fruit, also known as guanabana, guyabano, or soursop fruit is not significant when it comes to cancer fighting effects, but there are studies that claim the complete opposite. Namely, the studies have discovered that this fruit has features that are pretty beneficial when it comes to fighting cervical, colon, prostate, lung, lymphoma, ovarian, breast, liver and pancreatic cancer.
This One Fruit Kills Malignant Cells Of 12 Different Types Of Cancer
As to pancreatic cancer, graviola has been proven to be effective in reducing the tumorigenicity, as well as for changing the metabolism of the pancreatic tumor cells. This was discovered and revealed by a pathologist at the University of Nebraska.
A laboratory study also proved that graviola is 10,000 times more potent in killing colon cancer cells than Adriamycin, a drug that is commonly and widely used in chemotherapy. Another considerable difference between graviola and chemotherapy is that the graviola kills the cancer cells only, without doing harm to the healthy cells.
Another study discovered that the extract from graviola can slow down the growth of breast cancer cells. According to data from the study, the dietary GFE triggered considerable growth inhibition of MDA-MB-468 cells in vitro and in vivo studies through a mechanism that engages the EGFR/ERK signaling pathway, suggesting that GFE might have a protective impact for women against EGFR- over-expressing BC.
What about cervical cancer? Soursop was beneficial in treating this cancer, too, as evidenced in this scientific journal. Not only these, there are more studies on the topic of graviola and its impacts on fighting different types of cancer. It is a fruit that contains powerful anti-cancerous agents known as acetogenins, which are the substances that play the most important role towards numerous varieties of cancer. The acetogenins are pretty powerful inhibitors of NADH oxidase of the cancer cells’ plasma membranes.